Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer.

Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, Fronick C, Cook L, Snider JE, Davies S, Kavuri SM, Chang EC, Magrini V, Larson DE, Fulton RS, Liu S, Leung S, Voduc D, Bose R, Dowsett M, Wilson RK, Nielsen TO, Mardis ER, Ellis MJ.

Nat Commun. 2018 Nov 14;9(1):4850. doi: 10.1038/s41467-018-07407-3.

2.

The prognostic effects of somatic mutations in ER-positive breast cancer.

Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, Fronick C, Cook L, Snider JE, Davies S, Kavuri SM, Chang EC, Magrini V, Larson DE, Fulton RS, Liu S, Leung S, Voduc D, Bose R, Dowsett M, Wilson RK, Nielsen TO, Mardis ER, Ellis MJ.

Nat Commun. 2018 Sep 4;9(1):3476. doi: 10.1038/s41467-018-05914-x. Erratum in: Nat Commun. 2018 Nov 14;9(1):4850.

3.

Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.

Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S, Sørlie T, Leung S, Fan C, Perou C, Gelmon K, Overgaard J, Voduc D, Prat A, Cheang MCU.

Acta Oncol. 2018 Jan;57(1):38-43. doi: 10.1080/0284186X.2017.1401735. Epub 2017 Nov 25.

PMID:
29172851
4.

Neoadjuvant systemic therapy in breast cancer: use and trends in radiotherapy practice.

Koulis TA, Beecham K, Speers C, Tyldesley S, Voduc D, Simmons C, Olson R.

Curr Oncol. 2017 Oct;24(5):310-317. doi: 10.3747/co.24.3558. Epub 2017 Oct 25.

5.

Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.

Liu FF, Shi W, Done SJ, Miller N, Pintilie M, Voduc D, Nielsen TO, Nofech-Mozes S, Chang MC, Whelan TJ, Weir LM, Olivotto IA, McCready DR, Fyles AW.

J Clin Oncol. 2015 Jun 20;33(18):2035-40. doi: 10.1200/JCO.2014.57.7999. Epub 2015 May 11.

PMID:
25964246
6.

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA.

Oncologist. 2015 May;20(5):474-82. doi: 10.1634/theoncologist.2014-0372. Epub 2015 Apr 23.

7.

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ.

Clin Cancer Res. 2010 Nov 1;16(21):5222-32. doi: 10.1158/1078-0432.CCR-10-1282. Epub 2010 Sep 13.

8.

Metastatic behavior of breast cancer subtypes.

Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K.

J Clin Oncol. 2010 Jul 10;28(20):3271-7. doi: 10.1200/JCO.2009.25.9820. Epub 2010 May 24.

PMID:
20498394
9.

HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients.

Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM.

Ann Surg. 2010 Jun;251(6):1107-16. doi: 10.1097/SLA.0b013e3181dbb77e.

PMID:
20485140
10.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.

11.

Supervised risk predictor of breast cancer based on intrinsic subtypes.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS.

J Clin Oncol. 2009 Mar 10;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370. Epub 2009 Feb 9.

12.

Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.

Voduc D, Nielsen TO.

Clin Breast Cancer. 2008 Dec;8 Suppl 4:S171-8. doi: 10.3816/CBC.2008.s.014. Review.

PMID:
19158038
13.

The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.

Voduc D, Nielsen TO, Cheang MC, Foulkes WD.

Hum Pathol. 2008 Oct;39(10):1431-7. doi: 10.1016/j.humpath.2008.03.004. Epub 2008 Jul 11.

PMID:
18620730
14.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

15.

Tissue microarrays in clinical oncology.

Voduc D, Kenney C, Nielsen TO.

Semin Radiat Oncol. 2008 Apr;18(2):89-97. doi: 10.1016/j.semradonc.2007.10.006. Review.

16.

GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.

Voduc D, Cheang M, Nielsen T.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):365-73. doi: 10.1158/1055-9965.EPI-06-1090.

17.

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.

Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG.

Breast Cancer Res Treat. 2008 Jan;107(2):249-57. Epub 2007 Mar 13.

18.

Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002.

Tyldesley S, Voduc D, McKenzie M, Duncan G, Liu M, Wu D.

Urology. 2006 Mar;67(3):594-8.

PMID:
16527585
19.

The effect of smoking on tumour oxygenation and treatment outcome in cervical cancer.

Fyles A, Voduc D, Syed A, Milosevic M, Pintilie M, Hill R.

Clin Oncol (R Coll Radiol). 2002 Dec;14(6):442-6.

PMID:
12512963

Supplemental Content

Support Center